BSE filing, NSE: MANGALAM. Summary written from the filing by ALFA Finder's alert engine.
Mangalam Drugs and Organics Ltd: key numbers
- Share price
- ₹29.10
- Market cap
- ₹46.06 Cr
- Revenue (annual)
- ₹232.1 Cr
- Net profit (annual)
- ₹-44.40 Cr
- P/E (TTM)
- -1.2×Sector 46.1×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mangalam Drugs and Organics Ltd
All →Mangalam Drugs and Organics Board Meeting Date
Mangalam Drugs will hold a board meeting on 5 November 2026 to consider unaudited September 2026 quarter results. The agenda is proposed only, pending the meeting.
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs issued a postal ballot notice seeking approval to re-appoint Praveen Saxena as independent director for a second five-year term. Voting closes 17 June 2026.
Mangalam Drugs and Organics Debt & Borrowing: ₹1,557 Cr
Mangalam Drugs and Organics Limited has reported a default amounting to Rs.1,557.27 Crore. The company has submitted a restructuring proposal to its banks to manage the obligation.
- Value
- ₹1,557 Cr
Mangalam Drugs and Organics Debt & Borrowing: ₹15.57 Cr
Mangalam Drugs and Organics Limited reported defaults on bank loan obligations totaling Rs. 15.57 Crore. The defaults involve cash credit accounts at Bank of Maharashtra and Bank of Baroda.
- Value
- ₹15.57 Cr
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs and Organics Limited has issued a Postal Ballot notice to seek shareholder approval for appointing Shri Prabhakar Raghunath Zavar as an Independent Director. The appointment is for five years.
Mangalam Drugs and Organics Other Announcement
Mangalam Drugs and Organics Limited announced the appointment of new Statutory and Secretarial Auditors following the tenure completion of the previous Statutory Auditor.
Other management change announcements
All →Ambani Orgochem Management Change
Ambani Orgochem announced the resignation of non-executive non-independent director Bhavin Patel, effective 29 October 2026. The resignation was attributed to professional priorities and commitments.
3i Infotech Management Change
3i Infotech appointed Shirsendu Chaudhuri as Chief Growth Officer, a senior management role, effective October 29, 2026. He brings over 22 years of experience in IT services, enterprise software and SaaS.
Travel Food Services Management Change
Travel Food Services appointed Avinash Yogeshwar as Senior Managerial Personnel, effective 29 October 2026. It is a senior leadership change with no financial impact.
Swan Defence and Heavy Industries Management Change
Swan Defence designated three existing employees as Senior Management Personnel effective 29 October 2026, following organisational restructuring. The move reflects leadership reorganisation, not new capital or contracts.
Prima Innovation Management Change
Prima Innovation Limited reported the resignation of Non-Executive Director Dilip M. Parekh, effective 29-10-2026, citing personal reasons. The exit is a board-level change investors should note.
Strides Pharma Science Management Change
Strides Pharma's board appointed Biren Gabhawala as Non-Executive Independent Director effective November 1, 2026, for five years. He is a Chartered Accountant with extensive audit and listed-company board experience.
- Execution
- Five-year term effective November 1, 2026